Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

LONDON— A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly "opens the possibility of an end to the ...

The freshly inked deal comes less than two weeks after BioAge discarded a phase 2 obesity trial and less than three months ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...

As the New Year approaches, many adults resolve to eat healthier or give the gym another try, but such resolutions are rare ...

Vermont now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Vermont covers just ...

For the first time in a decade, adult obesity in the United States dropped last year, a new study has found, and researchers are curious how the rise in popularity of weight loss drugs like ...

Obesity rates in the United States have finally started to show a decline, heading in the right direction for the first time in a decade likely due to the popularity of weight loss drugs like ...

The use of weight loss drugs may be helping reverse obesity trends, experts say. For the first time in over a decade, obesity rates in the United States may finally be heading in the right ...